Sabiha Gul
Research Subjects
Sabiha Gul has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Farzana Sadaf
Hamdard University
1 shared publication - Muhammad Azam
Hamdard University
1 shared publication Rahela Ikram
Department of Pharmacy, Salim Habib University, Karachi-Pakistan
1 shared publication- Sana Sarfaraz
Department of Pharmacology, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, 75270 Karachi, Pakistan
1 shared publication - Shoaib Mithani
Department of Pharmacology, Faculty of Pharmacy, Jinnah Sindh Medical University, Karachi-Pakistan
1 shared publication - Sumbul Shamim
Dow University of Health Sciences
1 shared publication
Latest Publications
- 30 September 2026
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 10 (3) , 305-317
Comparative Assessment of Garlina and Murraya koenigii L. in Alleviating Hyperlipidemia-induced Dysregulated Lipid Metabolism
Objective: This study aimed to evaluate the comparative assessment of Garlina and Murraya koenigii L. in hyperlipidemic rats.Material and Methods: In vivo antihyperlipidemic potential of different MURK (Murraya koenigii L.) extracts and Garlina was conducted on Wistar rats induced with high-cholesterol diet. All test samples were given at p.o. dosage of 50 mg/ kg and animals were observed for 60-days. Animal Food-intake and body weight along with lipid markers in liver and aorta were investigated. In addition to this, serum lipid biomarkers along with atherogenic index was also determined. The results compared with Atorvastatin treated group. Data is expressed as mean ± standard error mean (S.E.M) using ANOVA to determine significance. Results: MURK extracts significantly decreased body weight and food intake, in contrast to the Garlina and Atorvastatin groups. MURK-HEX (hexane) extract displayed the significant reduction of 3.83 ± 2.3 g in body weight. Similarly, MURK-hexane and MURK-EA (ethylacetate) also demonstrated the highest rate of reduction in food consumption, i.e., 65.62 ± 0.5 g and 64.61 ± 0.7 g respectively. Tissue levels of cholesterol and triacylglycerol (TAG) were measured in the liver and aorta. MURK-EA treated rats had the lowest liver cholesterol levels (130 mg/dl), while the group that received MURK-MeOH (methanol) had the lowest aortic cholesterol levels (120 mg/dl). Additionally, lower TAG levels in liver and aorta of MURK-MeOH treated group were observed, measuring 129 mg/dl and 139 mg/dl respectively. MURK-MeOH group also showed the lowest serum lipid markers, i.e., TAG, LDL, and cholesterol at 136, 144, and 48 mg/dl respectively. Further, the inverse relationship between atherogenicity index of plasma (AIP) and percent protection of treatment regime indicated that all treatment groups successfully control hyperlipidemia.Conclusion: Garlina and MURK extracts possess significant lipid lowering potential. Garlina enhanced the HDL serum levels and in turn, showed lowest AIP comparable to that of standard drug Atorvastatin.
- 30 September 2026
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 10 (3) , 305-317
Comparative Assessment of Garlina and Murraya koenigii L. in Alleviating Hyperlipidemia-induced Dysregulated Lipid Metabolism
Objective: This study aimed to evaluate the comparative assessment of Garlina and Murraya koenigii L. in hyperlipidemic rats.Material and Methods: In vivo antihyperlipidemic potential of different MURK (Murraya koenigii L.) extracts and Garlina was conducted on Wistar rats induced with high-cholesterol diet. All test samples were given at p.o. dosage of 50 mg/ kg and animals were observed for 60-days. Animal Food-intake and body weight along with lipid markers in liver and aorta were investigated. In addition to this, serum lipid biomarkers along with atherogenic index was also determined. The results compared with Atorvastatin treated group. Data is expressed as mean ± standard error mean (S.E.M) using ANOVA to determine significance. Results: MURK extracts significantly decreased body weight and food intake, in contrast to the Garlina and Atorvastatin groups. MURK-HEX (hexane) extract displayed the significant reduction of 3.83 ± 2.3 g in body weight. Similarly, MURK-hexane and MURK-EA (ethylacetate) also demonstrated the highest rate of reduction in food consumption, i.e., 65.62 ± 0.5 g and 64.61 ± 0.7 g respectively. Tissue levels of cholesterol and triacylglycerol (TAG) were measured in the liver and aorta. MURK-EA treated rats had the lowest liver cholesterol levels (130 mg/dl), while the group that received MURK-MeOH (methanol) had the lowest aortic cholesterol levels (120 mg/dl). Additionally, lower TAG levels in liver and aorta of MURK-MeOH treated group were observed, measuring 129 mg/dl and 139 mg/dl respectively. MURK-MeOH group also showed the lowest serum lipid markers, i.e., TAG, LDL, and cholesterol at 136, 144, and 48 mg/dl respectively. Further, the inverse relationship between atherogenicity index of plasma (AIP) and percent protection of treatment regime indicated that all treatment groups successfully control hyperlipidemia.Conclusion: Garlina and MURK extracts possess significant lipid lowering potential. Garlina enhanced the HDL serum levels and in turn, showed lowest AIP comparable to that of standard drug Atorvastatin.
- Open Access
- 3 July 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2301-2316
Double agent: how Escherichia coli switches from commensal to pathogen in the urinary tract infection
Escherichia coli exhibits a dual nature as both a beneficial gut commensal and the predominant cause of community-acquired urinary tract infections (UTIs) worldwide. This review synthesizes current evidence establishing phenotypic plasticity the capacity for dynamic, non-heritable, and reversible adaptation as a central determinant of uropathogenic E. coli pathogenesis, distinct from stable genetic resistance. From a multilayered perspective, a comprehensive analysis is provided of how genomic diversity, host-pathogen interactions at the bladder epithelium, and exposure to clinically relevant antibiotics collectively drive morphological and regulatory reprogramming. These adaptations include surface roughening, filamentation, and RpoS-mediated persistence, along with (p)ppGpp stringent response and EnvZ/OmpR two-component system signaling, which enhance bacterial survival independently of genetic resistance mutations. The review further discusses how these mechanisms establish a coordinated survival matrix, creating a fundamental disconnect between standard antibiotic susceptibility testing and the host-associated phenotypes that characterize actual infections. Unlike genetically resistant bacteria that grow at elevated antibiotic concentrations, phenotypically tolerant cells exhibit normal MICs but require prolonged killing times, explaining why recurrent UTIs occur despite appropriate therapy. Finally, recent advances, including phage vB_EcoP_P64441 combined with cefotaxime for biofilm disruption, glucose-mediated gentamicin tolerance targeting metabolic pathways, and HDAC inhibitors such as valproic acid for host-directed epigenetic reprogramming, offer new opportunities to break the debilitating cycle of recurrent UTIs affecting millions worldwide.
- 3 July 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2301-2316
Open AccessDouble agent: how Escherichia coli switches from commensal to pathogen in the urinary tract infection
Escherichia coli exhibits a dual nature as both a beneficial gut commensal and the predominant cause of community-acquired urinary tract infections (UTIs) worldwide. This review synthesizes current evidence establishing phenotypic plasticity the capacity for dynamic, non-heritable, and reversible adaptation as a central determinant of uropathogenic E. coli pathogenesis, distinct from stable genetic resistance. From a multilayered perspective, a comprehensive analysis is provided of how genomic diversity, host-pathogen interactions at the bladder epithelium, and exposure to clinically relevant antibiotics collectively drive morphological and regulatory reprogramming. These adaptations include surface roughening, filamentation, and RpoS-mediated persistence, along with (p)ppGpp stringent response and EnvZ/OmpR two-component system signaling, which enhance bacterial survival independently of genetic resistance mutations. The review further discusses how these mechanisms establish a coordinated survival matrix, creating a fundamental disconnect between standard antibiotic susceptibility testing and the host-associated phenotypes that characterize actual infections. Unlike genetically resistant bacteria that grow at elevated antibiotic concentrations, phenotypically tolerant cells exhibit normal MICs but require prolonged killing times, explaining why recurrent UTIs occur despite appropriate therapy. Finally, recent advances, including phage vB_EcoP_P64441 combined with cefotaxime for biofilm disruption, glucose-mediated gentamicin tolerance targeting metabolic pathways, and HDAC inhibitors such as valproic acid for host-directed epigenetic reprogramming, offer new opportunities to break the debilitating cycle of recurrent UTIs affecting millions worldwide.
- Open Access
- 1 June 2022
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 10 (2) , 195-201
Screening of different doses of lyophilized beetroot for their hematopoietic potential.
Background: Beetroots are considered a vital source of nutrition and are usually incorporated into the daily diet to prevent different disease conditions. The therapeutic effect observed is due to the presence of active ingredients in the vegetables. The majority of our population, especially females, suffers from anemia due to malnutrition. The perseverance of this research was to explore the hematopoietic effects of lyophilized beetroot powder at different doses so they could be recommended as a nutritional supplement. Methodology: Albino rabbits weighing 1500-2000 gm of either gender were selected for the study and alienated into three sets. Set I was administered distilled water, whereas sets II and III were given lyophilized beetroot 500 mg/kg and 1000 mg/kg, correspondingly. For hematopoietic evaluation of blood, automated huma count plus was utilized. After adjusting according to their weights, lyophilized beetroot powder was suspended in distilled water and given at 500 mg/kg and 1000 mg/kg to rabbits. They were dosed once daily for two months. Results: The effects were verified before the dosing was scheduled and on the 30th day and 60th day of dosing. The outcomes presented a highly noteworthy increase (pConclusion: From the above, it can be concluded that beetroot possesses pronounced hematopoietic effects and might be beneficial as a non-pharmacological treatment for anemia and thrombocytopenia.
- 1 June 2022
- Published by Advance Educational Institute and Research Center (Publications) in International Journal of Endorsing Health Science Research (IJEHSR)
- Vol. 10 (2) , 195-201
Open AccessScreening of different doses of lyophilized beetroot for their hematopoietic potential.
Background: Beetroots are considered a vital source of nutrition and are usually incorporated into the daily diet to prevent different disease conditions. The therapeutic effect observed is due to the presence of active ingredients in the vegetables. The majority of our population, especially females, suffers from anemia due to malnutrition. The perseverance of this research was to explore the hematopoietic effects of lyophilized beetroot powder at different doses so they could be recommended as a nutritional supplement. Methodology: Albino rabbits weighing 1500-2000 gm of either gender were selected for the study and alienated into three sets. Set I was administered distilled water, whereas sets II and III were given lyophilized beetroot 500 mg/kg and 1000 mg/kg, correspondingly. For hematopoietic evaluation of blood, automated huma count plus was utilized. After adjusting according to their weights, lyophilized beetroot powder was suspended in distilled water and given at 500 mg/kg and 1000 mg/kg to rabbits. They were dosed once daily for two months. Results: The effects were verified before the dosing was scheduled and on the 30th day and 60th day of dosing. The outcomes presented a highly noteworthy increase (pConclusion: From the above, it can be concluded that beetroot possesses pronounced hematopoietic effects and might be beneficial as a non-pharmacological treatment for anemia and thrombocytopenia.